Supplementary information Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
2001 Dec;27(8):817-27
AOD vs GLP-1 GLP-1 agonists (semaglutide, tirzepatide) are our primary medical weight-loss lane with the strongest evidence
Mild headache during the first week
However, while these alleged benefits exist, scientific evidence supporting their efficacy still needs to be improved
[16] Lauritano E, Bilotta A, Gabrielli M et al